initi price target
back basic hip shoulder knee toe
part roll-out orthoped sector initi coverag
zimmer biomet rate pt
repres price upsid current level pleas see
link et webinar brief summari
link et webinar click
summari thesi share trade meaning discount
peer market new ceo helm promis lead
turnaround natur question rate
high regard new ceo bryan hanson believ
right person job said think turnaround
could take littl longer expect
new product like tailwind first need
get around issu resolv manufactur issu full
resumpt suppli like push sale
reacceler like time frame
final much need invest turnaround busi
like limit oper leverag medium term
see ep grower medium term
pt equat blend price-to-earnings line recent
trade level dcf impli tgr
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
back basic hip shoulder knee toe
last page report import disclosur regard stock report
tabl content
ii segment overview product
read stock chart
debat joint recon start grow market rate risk thesi
debat els new ceo bryan hanson creat sharehold valu
debat peak margin
 model valuat
vi invest thesi risk
zimmer biomet largest player orthoped
found justin zimmer
zimmer market first hip prosthesi
zimmer market first metal-plast total knee prosthesi
spun bristol-my squibb began trade
acquir extraortho expand extern fixat offer
acquir biomet chang name zimmer biomet
acquir ldr hold enhanc spine busi
geograph mix america vs emea/ apac
tenur team legaci zimmer biomet
compani file base annual result
name ceo prior role formerli
covidien evp group presid year
prior cfo cfo biomet control
held role bard
previous biomet vice-president gener manag bone cement
prior role presid biomet sport medicin extrem
previous biomet vice-president gener manag craniomaxillofaci
thorac
compani file base result
bmet deal org revenue lsd
deal margin compress rev decel
impact
de-lever debt paydown primari focu mt
evercor isi compani file
marginsoper margin repurchasesfre segment overview product
zimmer biomet gener bn revenu report main segment
knee total rev bn implant instrument osteoarthr persona person
hip total rev bn solut hip arthroplasti zimmer m/l taper hip prosthesi
 compani rev bn grow mid-singl digit
sport medicin devic repair soft tissu injuri juggerknot soft anchor system
extremities/foot ankl product treat arthrit condit foot ankl shoulder elbow
trauma product stabil damaged/broken bone natur nail dvr plate
biolog materi use earli intervent joint preserv gel-on cross-link hyaluron
dental compani rev mm declin low singl mid singl digit
consist dental implant prosthet regen product taper screw-vent implant
implant puro allograft
spine cmf compani rev mm grow low-singl digit
spine cmf total rev instrument back neck pain well product face
joint reconstruct largest segment bn rev
player joint reconstruct hip knee make compani revenu
portfolio implant tool total partial replac well
revis repair procedur
patella knee cap tibial tray articular surfac place
portfolio implant tool hip replac surgeri
total hip replac surgeri replac head femur
socket portion pelvi acetabulum use bone cement attach
prosthet compon surround bone press-fit bone
surfac bone affix either ongrowth ingrowth
type develop
anatom
increment knee
 wide use
pcl tact
interchang
size level bear
referenc hip stem
substrat porou
implant combin
 modular system shell
establish stabl joint
joint reconstruct knee contribut bn sale
knee bn market grow lsd-msd
player knee
compani file evercor isi base actual revenu
market segment product class
grow market due suppli constrain
compani file evercor isi peer consist compani market share graph
joint reconstruct hip contribut bn sale
hip bn market grow lsd
player hip
market segment product class
histor grown market
compani file evercor isi peer consist compani market share graph
 second largest segment bn sale
surgic sport medicin extrem trauma account total compani sale
rang product measur patient pressur manag fluid
wast power tool surgic saws/blad compress therapi
product primarili repair soft tissu injuri commonli
use knee shoulder
devic design treat arthrit condit fractur foot
ankl shoulder elbow wrist
tool use stabil damag broken bone surround
tissu support bodi natur heal process
pump use remov
 appli
pressur cuff
devic soft tissu
gel treat knee
surgic fluid
fixat bone
smoke surgeri
system return cuff
normal
use bone fixat
 plate screw
system use distal
 extrem trauma repres rev
compet bn market grow hsd
extrem trauma
market segment product class
return averag growth
compani file evercor isi peer consist compani market share graph
 sport repres rev
compet sever surgic market grow msd
top player tool small sport
compani file evercor isi base actual revenu
sport medicin market segment product
abl
maintain growth
segment new
spine/cmf dental contribut bn rev
spine cmf largest sub-seg grow low mid singl digit
medic devic surgic instrument back neck pain caus
degen condit deform traumat injuri spine
face skull reconstruct product product fixate/stabil
bone chest open heart surgeri trauma deform
dental reconstruct implant miss teeth prosthet restor
teeth regen product soft tissu bone rehabilit
primarili includ bone cement offic base technolog product
spinal fusion stimul
system util
fusion system
interbodi spacer
technolog allow
polyethylen core
slide rotat insid
 plate design
facilit fixat
design bone
disc react
surfac insuffici
bone height design
convent
 cmf dental april
spine/cmf seen faster histor growth vs peer
top player spine market
compani file evercor isi base revenu
launch sigma spectrum drive growth us
overal spine market snapshot product class
spine market weaken late
mf plate
compani file evercor isi peer consist compani market share graph
organ growthweight read stock chart
share in-lin rang bound post deal
delay deal closur month announc manufactur suppli constrain drag
join ceo
delay deal closur
miss expect due
stock price direct follow revenu surpris
total move last year
move
move
govern manag compens analysi
bryan hanson compens tie hurdl base stock price perform
one time equiti award worth mm subject ceo hanson purchas mm stock
within day dec average price
nqsq non qualifi stock option worth mm vest yr prsu
perform base rsu worth mm vest dec anniv
mm prsu vest anniversari subject stock appreci
addit also award one-tim equiti replac award worth mm
mm nqsq mm rsu mm prsu perform base
mm prsu vest time stock appreci
final ceo hanson grant equiti award worth mm
compani file bonu includ one-tim cash bonu intend replac portion forfeit award hanson prior employ
gener manag abl hit annual target determin annual incent pay
board target set februari management guidanc mid-pt set jan/feb call actual resultsdid management meet target constant currenc revenue adjust oper profitfre flowadjust epsadjust epsconst currenc revenue adj oper profitfre flowadjust epsrevenu growthoper incom growthfre equiti april
bn
note guidanc fy initi previou year upward revisions/beat highlight green downward revisions/miss red
see key debat shape share perform mt
joint recon growth normal post resolut suppli chain issu risk
could caus grow market
made largest acquisit co histori june acquir rival biomet
becom largest orthoped compani
recent integr challeng emerg result suppli shortag
impact organ sale growth primarili hip knee portfolio
addit sale slow product line well spine dental
els new ceo bryan hanson creat sharehold valu
zbh former ceo resign toward middl decemb bryan
hanson formerli cov appoint role
kind arrow new ceo quiver turn busi drive
chang major sale forc indirect direct employe
sustain current margin profil
peak margin invest new ceo hanson drag margin
joint recon start grow market rate
risk thesi
reconstruct use major driver organ rev
pre prior biomet deal announc joint recon drove zbh organ growth
shoulder total ankl
organ growth driven hip knee
suppli challeng caus contribut
joint recon overal organ growth plummet
note pre includ surgic includ impact
organ sale growth suffer post issu emerg compani warsaw north facil
contribut organ sale
growth hip knee deterior
return full product suppli capac
new product launch reacceler sale growth
suppli challeng initi expec resolut slip
unanticip suppli constraint relat transit suppli chain infrastructur
continu make progress toward enhanc improv suppli chain manufactur
qualiti system replenish safeti stock key cross-sel product throughout first half
experienc greater-than-expect number temporari occasion product delay
reach full product certain brand proven challeng initi anticip
due complex valid certain materi type product process well ensur
qualiti control regard sourc
complex manufactur process well increas attrit begin august among
lower anticip product output sever key brand due inconsist yield certain
temporari direct labor workforc warsaw
act ceo florin note call achiev full suppli
product
suppli challeng ceo hanson see risk timelin
latest earn call ceo bryan hanson express caution head sale recoveri
believ risk opportun timelin see
take suppli recoveri turn translat actual acceler revenu
growth think go delay mayb your think mayb
even thought came
sequenti growth compon inventori wip increas
qoq increas work
suggest qc process
strain worker
abl convert inventori
finish good
support ceo view
risk timelin
work progress
suppli challeng histori warn letter
letter fda cite concern
manufactur valid
process trilog acetabular
system ponc puerto rico
fda request addit info
evalu adequaci biomet respons
relat zhejiang china facil
jan
june warn letter fda
request relat zhejiang china
facil close
letter relat manufactur
pend process
facil montreal canada languag
becam harsh note
possibl corpor warn letter
recidivist warn letter consent decre
perman injunct well potenti
prosecut doj
observ
track respons fda relat observ fda
highlight novemb inspect
suppli challeng issuanc warn letter unlik
length time sinc issuanc make less like could receiv warn letter rare
continu make progress reach full suppli though challeng
like remain overhang remaind
given amount time pass sinc initi observ
think receipt fda warn letter unlik
return full suppli like push prior end late
rosa next line surgic robot system
system multipl indic
zimmer biomet preview rosa robot surgic system
aao meet though compani
continu keep detail product wrap
rosa support three zbh total knee platform persona
vanguard
rosa featur differ approach versu mako system
cut bone howev specif remain unknown
given channel check know thing
one featur tout rosa requir
rosa robot surgic system work launch
use robot specif rep oper system
use algorithm zimmer biomet bone atla databas
convert x-ray workabl model
design element x-ray base time net neutral
found tidbit interest hire number
makoplasti rep support physician usag adopt
system
makoplasti specialist
rosa rosa join number exist player
us
mm fb
error
case accuraci
angular
translat
feedback
average error
mm sd
within neutral
mm fl
case
complic tha
mm fl
plan model
registr point
stop motion
american journal orthoped medic robot minim invas surgeri bone compani file evercor isi
rosa first human end year launch aao
target tka launch aao impli month limit commerci ramp
plan launch rosa surgic robot system total knee arthroplasti limit basi end
limit launch includ develop addit physician
manag express confid launch timelin driven fact rosa alreadi approv brain spine applic
comparison took month move limit commerci launch tka
given zbh comment launch rosa robot platform
aao would impli limit launch around
end
comparison took month move limit
launch full commerci launch
launch rosa like benefit syk first mover statu advantag
launch spine brain applic
rosa rosa could add recon growth
think system placement conserv estimate given could place system
placement
mm capit sale
bp joint recon growth
see partial knee replac next launch rosa surgic robot system
addit indic follow like long term natur
total hip replac gener higher patient satisfact rate believ adopt robot techniqu improv
applic total knee partial knee total hip rosa abl effect compet versu syk mako surgic robot
term product offer
manag comment continu invest robot technolog continu iter
rosa use x-ray mage construct model interest could lower imag cost
rosa like meaning contributor could add bp growth joint
portfolio last year
combo bmet acquisit forc divest
select asset includ fix bear partial knee
sold smith nephew
persona partial fix bear partial knee base
prior partial knee year survivorship
data
launch world-wide
partial knee small piec market persona partial allow compet segment knee market
zbh share
demand persona partial strongand abl drive increment share gain
within mm market
new product cementless knee launch increment
cement tka standard carebut cementless gain traction given advantag good outcom
cement tka standard care prior gener cementless technolog show less optim result
said use bone cement drawback includ
increas time procedur estim bone cement add minut per case averag
releas carcinogen exposur oper team
cementless advantag bond occur true bone ingrowth stronger versu bond creat bone cement
dynam make cementless amen younger patient like implant longer period time
versu older patient recent data state total knee replac patient year
uk data show revis rate cementless compar expect continu trend toward cementless knee
tka done yr old patient
tka
new product revis knee launch anoth increment
persona trabecular metal tibial knee cementless expect commerci launch
cementless product offer boost sale growth though could gradual
previous cementless trabecular metal tibial knee implant market though devic recal report loosen
howev asp cement system launch benefit sale growth begin back half
zbh share
revis fill anoth portfolio gap fill
revis approxim broader knee replac market
plan launch persona revis limit basi fill anoth histor gap within portfolio
new product launch cementless revis partial knee
contribut bp larg joint recon revenu
conclus joint recon could grow lsd
impact day
return
risk timelin
rosa limit launch
partial benefit
sale growth
commentari around risk timelin revenu acceler full suppli go
delayedmayb even ceo bryan hanson thought came suggest like
transit year
conclus pathway growth
prior suppli constraint joint recon sale growth averag
growth hip averag sale
growth
assum fulli suppli resumpt end zbh joint recon could grow
return full
growth joint
recon
chang new ceo bryan hanson implement
bryan hanson appoint ceo decemb
inherit busi alreadi midst sale growth challeng
growth averag
begin
three immedi item hanson need address
suppli issu instil confid timelin given prior slippag
invest sustain growth longer term
execut recent perf highlight sale execut
mitg averag mid singl digit sale growth hanson tenur
impact less sell day
ex sale growth would
mdt acquisit cov hanson serv presid minim invas therapi group
sale divis averag mid singl digit growth tenur
time hanson also divest select piec busi longer made strateg sens made sever
execut execut histori cov target
hanson bonu payment cov show sale outperform target set bod wide margin
achiev bonu payment metric
hanson deliv
sale growth oper incom target
respect busi unit year
interestingli hanson deliv sale growth
target within divis total co sale
ceo hanson oper background drive turn zbh sale
prior track record support thesi question remain much
time might take els improv perform
execut timelin could push trust rebuilt
latest earn call hanson express caution timelin
learn year think peopl run complex project thing never go plan
unplan event alway occur result know kind spidey sens look
believ risk opportun timelin see come complex histori
project like usual see slippag see peopl pull
feel timelin weve commun past end recoveri possibl dont want take
tabl feel that possibl said think there risk probabl timelin opportun
think ceo bryan hanson updat timelin upcom call
like provid greater degre visibl certainti investor
given prior track record cov
visibl confid perhap even import sale
organ promis suppli resumpt doc go
back mea culpafor revenu acceler post suppli
resumpt crucial gain sale organ trust
reason think ceo hanson like cautiou time
corpor cultur person lead cultur chang
sinc join hanson met employe basewhich astound us given short time frame
hanson person met zbh current employe
base plan continu trend
strategi deviat prior manag team
think simpl act meet sale distributor person
like moral booster
perhap even impress ceo hanson abil meet
larg number employe within short timewhich bring
new energi level organ
invest earli action indic step taken drive nt growth
latest earn call hanson express caution timelin
clear plan reinvest tax save busi drive top line growth
go bia near-term growth go focu commerci organ
seen math bulk mm tax save like reinvest sale
organ bolster perform suppli normal
remain invest longer term project
bp lower
tax rate vs
bn pre-tax
mm tax save
reinvest mainli
commerci organ
corpor side manag call mm bonu payment headwind
corpor paid due miss target increment payment help
conclus ceo hanson take right step rebuild trust
drive cultur chang incentiv sale organizationwhil
timelin could shift chang provid comfort mt
trajectori compani
peak margin opportun
grown ep similar despit rev lag
ep growth trend suggest control cost meaning possibl curtail invest
question need make signific invest make
histor phase low invest rate kind opportun
drive gm expans oper leverag beyond
gross margin decreas bp last year
mix impact declin structur
higher versu line snn much delta vs mix impact
zbh gross margin line
snn benefit higher
biolog franchis well wound
syk gross margin lower given
mix medsurg sale carri lower
gross margin said
diversif help achiev
market organ sale growth
gm delta vs mainli mix impact believ
margin in-lin industri
gross margin price consist hw
fx hedg recent turn neg along rise manufactur cost per unit
hw higher average cost per unit point impact
manufactur suppli issu
impact margin priceavg cost per unitobsolet inventoryfx hedgestot april
gross margin footprint analysi suggest scope exp
effici despit suppli challeng
compar sale cog per squar foot
closest peer
zbh sale sq ft lower versu impli
syk lower asp product due medsurg
segment equat lower rev/sq foot
vs zbhand invers suggest
effici
zbh rev/sq ft normal syk level would impli shrinkag sq ft
squar footag reduct provid
gm leverag time
gross margin could see slight expans mt
bottom-line price continu bp drag forese futur
think fx hedg continu remain headwind current rate albeit
magnitud impact smaller
normal manufactur issu averag cost per unit metric begin
improv aid gross margin
over-earn rel peer higher
product revenu mix
think could see slight improv go forward
price off-set manufactur effici fx hedg
impact swing factor
op margin deal synergi go
synergi off-set gm declin mix impact lower biomet margin
bp mix
biomet om
high
realiti oper margin declin bp past year
seem us lower revenu growth impact zbh
abil deriv oper leverag
op margin merger headcount remain fairli flat
increas headcount sinc due bmet merger
headcount like go slightli manag point invest
commerci organ
declin sale product hamper leverag
sg per employe roughli in-lin peerssuggest
over-earn rel peersand higher margin function
op margin see limit oppti sg leverag nt
sinc sg margin averag invest like maintain current level
comment invest
leverag mt like
zbh sg margin middl packwhich mostli function mix
margin higher syk
less snn
op margin like see increas invest
 low end versu peer
like step given hanson focu
got spend research develop bring innov help us
near term also help us longer term
bottom-line invest busi like drag
margin medium term
cap deploy abil tuck-in
assum ev/rev could acquir mm rev bp top-line
mm dividend payment
bn debt paydown
bn
capit
believ manag like focus execut
unlik deal could potenti distract
conclus see msd ep grower
bp om expans
margin expans
bn debt paydown
contribut
need reacceler revenu organ deriv meaning
oper leverag seem difficult present circumst
see like mid singl digit ep grower
financi model valuat
financi outlook evercor isi versu street
gener line street sale
street ep
organ sale growth fy fy
gross margin fy fy respect
oper margin fy fy respect
tax rate fy fy
share count mm fy fy
dcf valuat pt impli tgr
ebita margin versu current ebita margin
weight averag capit wacc
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu april
pt impli blend price-to-earnings multipl in-lin current histor trade averag
pt equat blend price-to-earnings multipl
pt impli rel discount vs gener in-lin year histor averag
macro team assum target price-to-earnings
base multipl pt impli
price-to-earnings equat forward discount vs
discount vs gener in-lin
compani year trade averag
histor p/ep/ impli yr yr premium vs april
note yield price-to-earnings base current stock price
million except per share data fy end decemb organ gp less ep share inc net inc price-to-earnings prem disc invest thesi risk
initi coverag rate price target
reconstruct like regain sale momentum increas visibl occur
histor joint reconstruct contribut zbh organ sale growth though recent suppli challeng
caus quit disrupt
resolut suppli challeng like slip prior estimate year end
new product cementless revis robot rosa provid benefit unlik see full
benefit
new ceo bryan hanson initi step suggest cultur chang like yield benefit mt
turnaround stori heavili depend tone cultur set new manag team
believ ceo hanson proactiv meet sale commit sale invest like boost moral
bring new energi level organ
said invest like take time yield benefit near term upsid
invest like cap oper leverag see zbh ep power msd rang low end peer group
dont think over-earn rel peer fx hedg headwind higher unit cost manufactur
invest like limit gm expans
commentari around invest sale organ impli oper leverag like minim
debt paydown help poor convers like limit abil pay debt faster see
ep grower medium term
conclus valuat like new ceo bryan hanson say believ expertis drive
turnaround like take time ep growth low end peer group mt given prefer
remain sidelin get clearer path acceler pt equat blend price-to-earnings multipl
impli price upsid current level
risk thesi
faster expect return full product suppli
faster expect uptak new product includ cementless revis could drive knee sale growth upper end
mid singl digit
faster expect adopt rosa competit share gain market incumb
greater expect invest result margin contract
delay reach full product suppli limit organ sale growth joint reconstruct
slower expect custom sale forc recept post complet suppli issu
pt equat blend price-to-earnings line recent trade level dcf impli tgr
upsid faster expect return full product suppli faster expect uptak new product includ cementless
revis could drive knee sale growth upper end mid singl digit faster expect adopt rosa
competit share gain market incumb
downsid greater expect invest result margin contract delay reach full product suppli limit organ
sale growth joint reconstruct slower expect custom sale forc recept post complet suppli issu
articl articl
time dissemin april et
analyst vijay kumar primarili respons prepar research report attest follow view opinion
render research report reflect person view subject compani issuer part research
analyst compens directli relat specif recommend view research report
